iOrganBio Appoints AI and Life Sciences Investor Jessica Owens to Board of Directors

iOrganBio, an innovator in intelligent cell manufacturing, announced today the appointment of Jessica Owens to its Board of Directors. Owens brings over 20 years of company-building and investing experience at the intersection of life sciences, health technology, and artificial intelligence, which iOrganBio says will be invaluable as it scales its CellForge platform and expands partnerships.

Owens co-founded GRAIL, a healthcare company that raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson. She also serves as co-founder and General Partner at Initiate Ventures. Her expertise in scaling companies and navigating the biotech landscape aligns with iOrganBio’s mission to redefine how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs).

iOrganBio’s CellForge platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. The platform is powered by the company’s functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver accuracy, efficiency, and quality for disease modeling, regenerative medicine, and drug development.

The appointment comes as iOrganBio seeks to advance AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies. Owens’ counsel is expected to help the company navigate the complexities of scaling its technology and forging strategic partnerships. iOrganBio is based at BioLabs in Chapel Hill, NC.

Jessica Owens’ addition to the board underscores the growing importance of AI in biotechnology and the need for experienced leadership to bridge the gap between innovation and commercialization. Her track record in building high-growth companies and securing major partnerships positions iOrganBio to potentially accelerate its impact on the cell manufacturing industry.

This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is iOrganBio Appoints AI and Life Sciences Investor Jessica Owens to Board of Directors.

The post iOrganBio Appoints AI and Life Sciences Investor Jessica Owens to Board of Directors appeared first on citybuzz.